Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir as add-on therapy in Glioblastoma
NCT04116411Phase 2Active, not recruiting
- Start
- Sep 2019
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in glioblastoma multiforme (GBM) comparing Placebo with Valganciclovir (2 arms). Primary endpoints: Overall Survival at 30 months and Baseline and demographic data at 30 months. Started Sep 2019; status: active, not recruiting.
02
Drugs
valganciclovir
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT04116411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116411.